The TEAMM trial results were presented at The American Society of Haematology Conference in December 2017.
Tackling Early Morbidity and Mortality in Myeloma (TEAMM): Assessing the Benefit of Antibiotic Prophylaxis and Its Effect on Healthcare Associated Infections in 977 Patients: http://www.bloodjournal.org/content/130/Suppl_1/903
Diagnostic Pathways of Myeloma Patients Presenting to Hospital Care and Relationship to End Organ Damage: An Analysis from the Teamm (Tackling EArly Morbidity and Mortality in Myeloma) Trial in 977 Patients: http://www.bloodjournal.org/content/130/Suppl_1/2132
Assessment of Anti-Bacterial Antibodies in Multiple Myeloma Patients at Disease Presentation and in Response to Therapy, Implication for Patient Management: http://www.bloodjournal.org/content/130/Suppl_1/3036
Thank you to all of the patients and hospitals that took part in the trial.
Any enquiries please email
teamm at warwick dot ac dot uk